Clarithromycin (Biaxin®) extended-release tablet: a therapeutic review

References

• Berg JS, Dischler J, Wagner DJ, Raia JJ, Palmer-Shevlin N. Medication compliance: a healthcare problem. Ann. Phatmacother. 27(9 Suppl.), S1-24 (1993).
   PubMedGoogle Scholar
• Branthwaite A, Pechere JC. Pan-European survey of patients' attitudes to antibiotics and antibiotic use. j Int. Merl Res. 24(3), 229–238 (1996).
   PubMed Web of Science ®Google Scholar
• Notario G, Takker U, Dzyublyk O, etal Comparison of five days of extended-release clarithromycin versus ten days of penicillin V for the treatment of streptococcal pharyngitis/tonsillitis: Results of a multicenter, double-blind, randomized study. Curr. Med. Res. Opin. (In Press).
   Google Scholar
• Alvarez-Elcoro S, Enzler MJ. The macrolides: erythromycin, clarithromycin and azithromycin. Mayo Clin. Proc. 74, 613–634 (1999).
   PubMed Web of Science ®Google Scholar
• Piscitelli SC, Danziger LH, Rodvold Clarithromycin and azithromycin: new macrolide antibiotics. Gun. Pharmacokinet. 11,137–152 (1992).
   PubMed Web of Science ®Google Scholar
• Sturgill MG, Rapp RP. Clarithromycin: review of a new macrolide antibiotic with improved microbiologic spectrum and favorable pharmacokinetic and adverse effect profiles. Ann. Phatmacother. 26, 1099–1108 (1992).
   PubMed Web of Science ®Google Scholar
• Guay DR, Gustayson LE, Devcich KJ, etal Pharmacokinetics and tolerability of extended-release clarithromycin. Glitz Ther. 23, 566–577 (2001).
   Google Scholar
• Mazzei T, Mini E, Novelli A, et al Chemistry and mode of action of macrolides. j Antimicrob. Chemother. 31(Suppl. C), 1–9 (1993).
   PubMed Web of Science ®Google Scholar
• Steigbigel NH. Macrolides and clindamycin. Mandell GL, Bennett JE, Dolin R. Principles and Practice of Infectious Diseases (5th Edition). Churchill Livingstone, PA, USA, 366–382 (2000).
   Google Scholar
• Abbott Laboratories. Biaxine XL Filmtab®: (clarithromycin extended release tablets). Precribing information (online). Available from www.rxabbott.com/bxhd/bxx006.htm. 2002 June
   Google Scholar
• Felmingham D. Respiratory pathogens: assessing resistance patterns in Europe and the potential role of grepafloxacin as treatment of patients with infections caused by these organisms. I Antimicrob. Chemother: 45 (Topic T2), 1–8 (2000).
   Web of Science ®Google Scholar
• Mandell's Principles and Practice of Infectious Diseases (5th Edition). 1(27), 367 (2002).
   Google Scholar
• Gotfried MH. Comparison of bacteriologic eradication of Streptococcus pneumoniae by clarithromycin and reports of increased antimicrobial resistance. Gun. Ther. 22(1), 2–14 (2000).
   Google Scholar
• Doern GV, Brueggemann AB, Pierce G, et al. Prevalence of antimicrobial resistance among 723 out-patient clinical isolates of Moraxella catarrhalis in the United States in 1994 and 1995: results of a 30-center national surveillance study. Antimicrob. Agents Chemother. 40,1208-1213 (1996).
   Google Scholar
• Periti P, Mazzei T Clarithromycin: pharmacokinetic and pharmacodynamic interrelationships and dosage regimen. Chemother. 11, 11–27 (1999).
   Web of Science ®Google Scholar
• Rodvold IKA. Clinical pharmacokinetics of clarithromycin. Gun. Phatmacokinet. 37, 385–398 (1999).
   PubMed Web of Science ®Google Scholar
• Rodvold KA, Gotfried MET, Danziger LH, Sorvi RJ. Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers. Antimicrob. Agents Chemother. 41, 1399–1402 (1997).
   PubMed Web of Science ®Google Scholar
• Patel KB, Xuan D, Tessier PR, etal. Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. Antimicrob. Agents Chemother: 40 (10), 2375–2379 (1996).
   PubMed Web of Science ®Google Scholar
• Retsema JA, Brennan LA, Girard AE. Effects of environmental factors on the in vitro potency of azithromycin. Eur. Gun. May. Infect. Dir. 10, 834–842 (1991).
   PubMed Web of Science ®Google Scholar
• Palmer R, Shortridge D, Devcich K, etal Macrolide resistance prevalence in S. pneumoniae: surveillance study reports vs. clinical trial efficacy. 6th International Conference on the Macrolides, Azalides, Streptogramins Ketolides and Oxazolidinones 2002; January 23–26 Bologna (Abstract no. 8.07).
   Google Scholar
• Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann. Int. Merl 106, 196–204 (1987).
   PubMed Web of Science ®Google Scholar
• Adler JL, Jannetti W, Schneider D, Zhang J, Palmer R, Notario G. Phase III, randomized, double-blind study of clarithromycin extended-release and immediate-release formulations in the treatment of patients with acute exacerbation of chronic bronchitis. Clin. Ther. 22, 1410–1420 (2000).
   PubMed Web of Science ®Google Scholar
• Anzueto A, Fisher CL, Busman T, Olson CA. Comparison of the efficacy of extended-release clarithromycin tablets and amoxicillin/clavulanate tablets in the treatment of acute exacerbation of chronic bronchitis. Clin. Ther. 23, 72–86 (2001).
   PubMed Web of Science ®Google Scholar
• Notario G, Nalepa P, Dobryniewska M, etal Short-course therapy of acute bacterial exacerbation of chronic bronchitis: A double-blind, randomized, multicenter comparison of extended release vs. immediate release clarithromycin. CL117: Merl Res. Opin. (In Press).
   Google Scholar
• Niederman MS, Mandell LA, Anzueto A, etal. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy and prevention. Am. j Respir. Grit. Care Merl 163, 1730–1754 (2001).
   PubMed Web of Science ®Google Scholar
• Bartlett JG, Dowell SF, Mandell LA, etal Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Disease Society of America. Clin. Infect. Dis. 31, 347–382 (2000).
   PubMed Web of Science ®Google Scholar
• Mandell LA, Marrie TJ, Grossman RF, etal Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. Clin. Infect. Dis. 31, 383–421 (2000).
   PubMedGoogle Scholar
• Heffelfinger JD, Dowell SF, Jorgensen JH, etal. Management of community-acquired pneumonia in the era of pneumococcal resistance: A report from the Drug-Resistant Stmptococcus pneumoniae Therapeutic Working Group. Air/i. Intern. Merl 160, 1399–1408 (2000).
   PubMed Web of Science ®Google Scholar
• File TM, Tan JS. International guidelines for the treatment of community-acquired pneumonia in adults. Drugs 63, 181–205 (2003).
   PubMed Web of Science ®Google Scholar
• Bishai W Current issues on resistance, treatment guidelines and the appropriate use of fluoroquinolones for respiratory tract infections. Clin. Ther. 24, 838–850 (2002).
   PubMed Web of Science ®Google Scholar
• Gotfried MET, Dattani D, Riffer E, etal. A controlled, double-blind, multi-center study comparing clarithromycin extended release tablets and levofloxacin tablets in the treatment of community-acquired pneumonia. Clin. Ther. 24, 736–751 (2002).
   PubMed Web of Science ®Google Scholar
• Sokol WN, Sullivan JG, Acampora MD, etal. A prospective, double-blind, multi-center study comparing clarithromycin extended-release with trovatioxacin in patients with community-acquired pneumonia. Clin. Ther. 24, 605–615 (2002).
   PubMed Web of Science ®Google Scholar
• FDA guidance for industry. CAP-developing antimicrobial drugs for treatment. Available at: www.fda.govicderiguidance/2570dft.pdf Accessed February (2003).
   Google Scholar
• Murray JJ, Solomon E, McCluskey D, etal Phase III, randomized, double-blind study of clarithromycin extended-release and immediate-release formulations in the treatment of adult patients with acute maxillary sinusitis. Clin. Ther. 22, 1421–1432 (2000).
   PubMed Web of Science ®Google Scholar
• Piscitelli SC, Danziger LH, Rodvold Clarithromycin and azithromycin: new macrolide antibiotics. Clin. Pharmacokinet. 11,137–152 (1992).
   Google Scholar
• Guay DR, Gustayson LE, Devcich KJ, etal Pharmacokinetics and tolerability of extended-release clarithromycin. Gun. Ther. 23,566–577 (2001).
   Google Scholar
• Stratton CW. Get a handle on resistance before it gets a handle on you: the PROTEKT US Surveillance Study. Prospective Resistant Organism Tracking and Epidemiology for Ketolide Telithromycin. South Med. 1. 94,891-892 (2001).
   Google Scholar
• Doem GV, Pfaller MA, Kugler K, etal Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY antimicrobial surveillance program. Gun. Infect Dis. 27,764–770 (1998).
   PubMed Web of Science ®Google Scholar
• Labro MT AntiInflammatory Activity of macrolides: a new therapeutic potential? Antimicrob. Chemother. 41, S37–46 (1998).
   Google Scholar
• Kohyama T, Takizawa H, Kawasaki S, etal Fourteen-member macrolides inhibit interleukin-8 release by human eosinophils from atopic donors. Antimicrob. Agents Chemother. 43,907–911 (1999).
   PubMed Web of Science ®Google Scholar
• CUBC O, Erakovic V, Pamham MJ. Anti-inflammatory effects of macrolide antibiotics. Eur. Pharmacol 429, 209–229 (2001).
   PubMed Web of Science ®Google Scholar
• Aoki Y, Kao PN. Erythromycin inhibits transcriptional activation of NF-KB but not NFAT, through calcineurin-independent signaling in T-cells. Antimicrob. Agents Chemother. 43,2678–2684 (1999).
   PubMed Web of Science ®Google Scholar
• Desaki M, Takizawa H, Ohtoshi T, etal Erythromycin suppresses nuclear factor-K B and activator protein-1 activation in human brochial epithelial cells. Biochem. Biophys. Res. Commun. 267,124–128 (2000).
   PubMed Web of Science ®Google Scholar
• Credito KL, Jacobs MR, Appelbaum PC. Activity of ABT-773 (a new ketolide) compared to 11 other drugs against H intluenzae by time-kill. 40th Interscience Confecynce on Antimicrobial Agents and ChemotherapySept 17,182 (2000).
   Google Scholar
• Ichiyama T, Nishikawa M, Yoshitomi T Clarithromycin Inhibits Nf-K B Activation in human peripheral blood mononuclear cells and pulmonary epithelial cells. Antimicrob. Agents Chemother. 45,44–47 (2001).
   PubMed Web of Science ®Google Scholar
• Miyanohara T, Ushigai M, Matsune A, Kurono Y. Effects of clarithromycin on cultured human nasal epithelial cells and fibroblast. Laryngoscope 110,126–131 (2000).
   PubMed Web of Science ®Google Scholar
• Jaffe A, Bush A. Anti-inflammatory effects of macrolides in lung disease. Fed. Pulm. 31,464–473 (2001).
   PubMed Web of Science ®Google Scholar
• Garey K, Alwani A, Danziger LH, Rubinstein I. Tissue reparative effects of macrolide antibiotics in chronic inflammatory sinopulmonary diseases. Chest 123,261–265 (2003).
   PubMed Web of Science ®Google Scholar
• Tamaoki J, Takeyama K, Tagaya E, Konno K. Effect of clarithromycin on sputum production and its rheological properties in chronic respiratory tract infections. Antimicrob. Agents Chemother. 39, 1688–1690 (1995).
   PubMed Web of Science ®Google Scholar
• Tagaya E, Tamaoki J, Kondo M, Nagai A. Effect of a short course of clarithromycin therapy on sputum production in patients with chronic airway hypersecretion. Chest 122,213–218 (2002).
   PubMed Web of Science ®Google Scholar
• MacLeod CM, Hamid 0A, Cameron L, etal Anti-inflammatory activity of clarithromycin in adults with chronically inflamed sinus mucosa. Adv Ther. 18(2), 75–82 (2001).
   PubMed Web of Science ®Google Scholar
• Yamada T, Fujieda S, Mori S, Yamamoto H, Saito H. Macrolide treatment decreased the size of nasal polyps and IL-8 levels in nasal lavage, A117. I Rhinology14,143-148 (2000).
   Google Scholar
• Garey K, Rubinstein I, Gotfried MET, etal Long-term clarithromycin decreases prednisone requirements in elderly patients with prednisone-dependent asthma. Chest 118,1826–1827 (2000).
   PubMed Web of Science ®Google Scholar
• Miyatake H, Taki F, Taniguchi H, etal Erythromycin reduces the severity of bronchial hyperresponsiveness in asthma. Chest 99,670–673 (1991).
   PubMed Web of Science ®Google Scholar
• Amayasu H, Yoshida S, Ebana S, etal Clarithromycin suppresses bronchial hyperresponsiveness associated with eosinophilic inflammation in patients with asthma. Ann. Allergy Asthma Immunol 84, 594–598 (2000).
   PubMed Web of Science ®Google Scholar
• Kraft M, Cassell GH, Pak J, Martin RJ. 4coplasma pneumoniae and chlamydia pneumoniae in asthma effect of clarithromycin. Chest121,1782-1788 (2002).
   Google Scholar